| Autor: |
Vogelsinger, Helene, Weiler, Stefan, Djanani, Angela, Kountchev, Jordan, Bellmann-Weiler, Rosa, Wiedermann, Christian J., Bellmann, Romuald |
| Zdroj: |
Journal of Antimicrobial Chemotherapy (JAC); June 2006, Vol. 57 Issue: 6 p1153-1160, 8p |
| Abstrakt: |
Objectives: Tissue concentrations of amphotericin B were determined in autopsy material of patients who had been treated with liposomal amphotericin B or amphotericin B colloidal dispersion (colloidal amphotericin B) for suspected or proven invasive fungal infection.Patients and methods: Amphotericin B tissue levels were measured in liver, spleen, lung, kidney, and myocardial and brain tissue of 20 patients who had been treated with lipid-formulated amphotericin B, before they died from multi-organ failure. Seven patients had been treated with liposomal amphotericin B (AmBisome®) and thirteen with colloidal amphotericin B (Amphocil®). Tissue samples were obtained during routine autopsy, homogenized and extracted with methanol. Amphotericin B concentrations were measured using HPLC after purification by solid phase extraction.Results: The highest amphotericin B levels were found in liver and spleen, followed by kidney, lung, myocardium and brain. In the lung higher amphotericin B concentrations were found after treatment with amphotericin B colloidal dispersion than after therapy with liposomal amphotericin B.Conclusions: The choice of lipid formulation may influence amphotericin B penetration into the lung. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
